News › Clinical Practice, Industry News

Lilly Sues Two Compounders Over Copies of Weight-loss Drugs

April 2, 2025

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.

This comes after a U.S. federal judge last month refused to allow compounding pharmacies to keep making copies of these drugs in the United States.

Compounders had been allowed to produce hundreds of thousands of doses of copies of obesity drugs only while the FDA said there was a shortage of them.

Lilly said the companies were selling unapproved drugs and making false claims about efficacy and safety.

The drugmaker says it will also send about fifty cease and desist letters to compounders and telehealth companies, asking them to confirm that they have already ceased mass compounding.

Read full coverage at Reuters >>

Find the latest updates on tirzepatide and semaglutide at our resource page: Medical Weight Loss in a Med Spa Practice.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics
    • Moxie Announces Treatment Plans
    • Pacific Reliance Medical M&A Advisors Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Misinformation on Hyaluronic Acid (HA) Fillers Taking Over Your Practice? A New Fact-Based Campaign by Allergan Aesthetics Sets the Story Straight